ArticleESMO open2026

Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies.

S B Maron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.